Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 11/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10117091 | 0.95 | P2RX3 (0.51) | P2RX3L3MBTL1ALDH1A1NPSR1HTT | |
| SCHEMBL10116913 | 0.93 | P2RX3 (0.57) | P2RX3RXFP1L3MBTL1HSD11B1NPSR1 | |
| SCHEMBL10116821 | 0.90 | MAPT (0.55) | P2RX3RXFP1L3MBTL1ALDH1A1NPSR1 | |
| SCHEMBL10116931 | 0.90 | P2RX3 (0.49) | P2RX3L3MBTL1ALDH1A1NPSR1HTT | |
| SCHEMBL10116888 | 0.90 | P2RX3 (0.49) | P2RX3RXFP1HSD11B1ALDH1A1NPSR1 | |
| SCHEMBL10117108 | 0.87 | P2RX3 (0.56) | P2RX3L3MBTL1ALDH1A1SMN1; SMN2STING1 | |
| SCHEMBL10117089 | 0.86 | P2RX3 (0.50) | P2RX3ALDH1A1NPSR1HTTMAPT | |
| SCHEMBL10117084 | 0.85 | TP53 (0.49) | P2RX3ALDH1A1NPSR1HTTSMN1; SMN2 | |
| SCHEMBL10116828 | 0.85 | P2RX3 (0.56) | P2RX3ALDH1A1NPSR1SMN1; SMN2THRB | |
| SCHEMBL10117078 | 0.83 | P2RX3 (0.45) | P2RX3ALDH1A1SMN1; SMN2THRBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497263-B2 | Pyrrolinone derivative and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2013-07-30 | — | — | US | disclosed |
| US-8497263-B2 | Pyrrolinone derivative and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2013-07-30 | — | — | US | disclosed |
| US-8101644-B2 | Pyrrolinone derivative and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-20120010199-A1 | NOVEL PYRROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KAI HIROYUKI (JP) | 2012-01-12 | — | — | US | disclosed |
| US-20120010199-A1 | NOVEL PYRROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KAI HIROYUKI (JP) | 2012-01-12 | — | — | US | disclosed |
| US-20100210632-A1 | NOVEL PYRROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010199-A1 | NOVEL PYRROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | P2RX3, P2RX2, P2RX1 | P2RX3 1/4885RXFP1 31/4885L3MBTL1 4884/4885 |
| US-20100210632-A1 | NOVEL PYRROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | P2RX3, P2RX2, P2RX1 | P2RX3 1/4885RXFP1 31/4885L3MBTL1 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.